Rivastigmine is a reversible inhibitor of cholinesterase used for the treatment of mild to moderate Alzheimer disease and Parkinsonism. It works by increasing levels of two chemicals, acetylcholine and butyrylcholine, in the brain to help with communication between nerve cells.

The global Rivastigmine Market is estimated to be valued at US$ 516.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the Rivastigmine market is the growing adoption of digital healthcare. With telemedicine and remote patient monitoring becoming more common due to the pandemic, patients are now able to access healthcare services virtually through video conferencing with their doctors. This has made treatment with medications like Rivastigmine more accessible. The digitalization of healthcare is expected to drive the demand for Rivastigmine as it allows for easier refills and management of the treatment regimen.

Segment Analysis

The global rivastigmine market is segmented into oral and transdermal/topical segments. The oral segment currently dominates the market due to higher adoption of oral rivastigmine capsules and tablets globally. The oral segment accounted for over 80% share of the global rivastigmine market in 2022. However, the transdermal/topical segment is expected to witness faster growth during the forecast period owing to the better patient compliance offered by transdermal patches as compared to oral pills.

Key Takeaways

- The Global Rivastigmine Market Demand is expected to witness high growth, exhibiting a CAGR of 4.6% over the forecast period, due to the increasing prevalence of Alzheimer's and Parkinson's disease globally.

- Asia Pacific region is projected to be the fastest growing market for rivastigmine during the forecast period. The rising geriatric population and increasing healthcare expenditure in countries like China and India are the major drivers of the APAC rivastigmine market.

- North America currently holds the largest share of over 35% of the global rivastigmine market and is expected to continue its dominance over the forecast period, owing to higher adoption and availability of rivastigmine products in the region.

- Key players operating in the rivastigmine market are Novartis AG, Mylan Laboratories Inc., Actavis Generics UK Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Zentiva a.s., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., and Accord Healthcare Limited. The market is highly fragmented, with these players accounting for over 70% of revenue generated globally.

For more details on the report, Read-

https://www.zupyak.com/p/3946801/t/rivastigmine-is-estimated-to-witness-high-growth-owing-to-growing-alzheimers-disease-prevalence